Author: Dr Tim Ringrose

Payments to doctors by pharma are like an abscess that has been festering for a long time and that now needs to be lanced.

Star Trek’s character, Spock, would probably be entirely in favour of care.data and mystified at the objections from patients and healthcare professionals!

The pharma 1.0 model of exclusively using data from clinical trials to justify the need for new drugs should be reviewed since the cost of collecting sufficient data is becoming uneconomic, the process denies early access to these new therapies and the data does not truly represent how they will work in the real world.

To innovate in a cost-conscious healthcare market, where the high and often prohibitive price of new drugs is of critical concern, pharma companies must be more agile and responsive to their customers’ needs.

New treatments mean the outlook for patients suffering from myeloma has improved considerably in the past decade, as outlined in the therapeutic focus in the June issue of PharmaTimes Magazine (which can be accessed here).